2026 Global: Anti-Migraine Drugs Market -Competitive Review (2032) report
Description
The 2026 Global: Anti-Migraine Drugs Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for anti-migraine drugs market by geography and historical trend. The scope of the report extends to sizing of the anti-migraine drugs market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The anti-migraine drugs market is dominated by ten major companies driving innovation through CGRP-targeted therapies, triptans, and novel gepants, with leaders including Eli Lilly, AbbVie (formerly Allergan), Teva Pharmaceuticals, Amgen, and Novartis. Eli Lilly spearheads with Emgality (galcanezumab), a monoclonal antibody approved in 2018 for migraine prevention, reducing monthly migraine days by targeting CGRP ligands, while its pipeline advances oral gepants like Atogepant. AbbVie, via Allergan acquisition, bolsters its portfolio with Botox for chronic migraine and emerging gepants, holding key patents amid a shift to patient-friendly injectables. Teva's Ajovy (fremanezumab), FDA-approved in 2018 and expanded globally by 2021, offers autoinjector convenience for prophylaxis, competing directly with Lilly and Amgen products. Amgen partners with Novartis on Aimovig (erenumab), the first CGRP receptor antagonist approved in 2018, supported by real-world evidence for episodic and chronic cases, enhancing rural access.
Pfizer contributes with Zavegepant, a Phase II intranasal gepant for acute and preventive use, alongside historical triptans like rizatriptan repurposed in combinations. GlaxoSmithKline (GSK) maintains presence through established triptans like Imitrex (sumatriptan generics), focusing on acute relief amid pipeline diversification. Endo and Impax Laboratories (now Amneal) support generics and formulations like dihydroergotamine derivatives, addressing cost barriers in a market projected to hit $25 billion by 2025. Lundbeck, via Seattle BioPharmaceuticals, offers Vyepti (eptinezumab), an IV CGRP antibody for rapid prevention, with Lu AG09222 advancing to Phase III by 2026 for novel mechanisms. Biohaven Pharmaceuticals innovates with BHV-2100 in Phase II for acute treatment, building on CGRP expertise post-acquisition by Pfizer.
Recent FDA approvals underscore competitive intensity: Axsome Therapeutics' Symbravo (AXS-07) in January 2025 provides multi-mechanistic oral relief within two hours, combining meloxicam and rizatriptan despite cardiovascular warnings. Satsuma's Atzumi (dihydroergotamine nasal powder) followed in April 2025, emphasizing nasal delivery for faster onset. These entrants challenge incumbents, with AbbVie, Lilly, Teva, Amgen, and Pfizer dominating patents on CGRP antagonists and biologics, while trends favor oral therapies, long-acting injectables, and non-CGRP targets like PACAP. Market growth at 5% CAGR through 2033 reflects rising demand for effective, convenient options amid 30+ companies in pipelines.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for anti-migraine drugs market by geography and historical trend. The scope of the report extends to sizing of the anti-migraine drugs market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The anti-migraine drugs market is dominated by ten major companies driving innovation through CGRP-targeted therapies, triptans, and novel gepants, with leaders including Eli Lilly, AbbVie (formerly Allergan), Teva Pharmaceuticals, Amgen, and Novartis. Eli Lilly spearheads with Emgality (galcanezumab), a monoclonal antibody approved in 2018 for migraine prevention, reducing monthly migraine days by targeting CGRP ligands, while its pipeline advances oral gepants like Atogepant. AbbVie, via Allergan acquisition, bolsters its portfolio with Botox for chronic migraine and emerging gepants, holding key patents amid a shift to patient-friendly injectables. Teva's Ajovy (fremanezumab), FDA-approved in 2018 and expanded globally by 2021, offers autoinjector convenience for prophylaxis, competing directly with Lilly and Amgen products. Amgen partners with Novartis on Aimovig (erenumab), the first CGRP receptor antagonist approved in 2018, supported by real-world evidence for episodic and chronic cases, enhancing rural access.
Pfizer contributes with Zavegepant, a Phase II intranasal gepant for acute and preventive use, alongside historical triptans like rizatriptan repurposed in combinations. GlaxoSmithKline (GSK) maintains presence through established triptans like Imitrex (sumatriptan generics), focusing on acute relief amid pipeline diversification. Endo and Impax Laboratories (now Amneal) support generics and formulations like dihydroergotamine derivatives, addressing cost barriers in a market projected to hit $25 billion by 2025. Lundbeck, via Seattle BioPharmaceuticals, offers Vyepti (eptinezumab), an IV CGRP antibody for rapid prevention, with Lu AG09222 advancing to Phase III by 2026 for novel mechanisms. Biohaven Pharmaceuticals innovates with BHV-2100 in Phase II for acute treatment, building on CGRP expertise post-acquisition by Pfizer.
Recent FDA approvals underscore competitive intensity: Axsome Therapeutics' Symbravo (AXS-07) in January 2025 provides multi-mechanistic oral relief within two hours, combining meloxicam and rizatriptan despite cardiovascular warnings. Satsuma's Atzumi (dihydroergotamine nasal powder) followed in April 2025, emphasizing nasal delivery for faster onset. These entrants challenge incumbents, with AbbVie, Lilly, Teva, Amgen, and Pfizer dominating patents on CGRP antagonists and biologics, while trends favor oral therapies, long-acting injectables, and non-CGRP targets like PACAP. Market growth at 5% CAGR through 2033 reflects rising demand for effective, convenient options amid 30+ companies in pipelines.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.